[The efficacy of treatment with native lymphoblast alpha-interferon (Wellferon) in patients with chronic myeloleukemia].
Data are submitted on treatment with vellferon of patients with chronic myeloid leukemia (CML) in the chronic phase of the illness. The data obtained suggest that vellferon has a pronounced therapeutic effect in CML patients. The drug has a positive effect on both the clinical- and hematological status and cytogenetic changes in bone marrow cells. After 3-month treatment of patients with vellferon the sizes of the liver and spleen returned to normal as did the peripheral blood leucocyte and platelet counts. Two patients revealed a minimum cytogenetic response to therapy, one patient achieved a complete cytogenetic remission, and only 1 patient failed to demonstrate a cytogenetic response. A six-month therapy was associated with a complete clinical-and-hematological remission in 4 (80%) patients, with its duration ranging between 4 to 5 months, all patients maintaining a minimum cytogenetic response to vellferon treatment. Thus, treatment with vellferon permits obtaining not only a clinical and hematological but also a cytogenetical response to therapy in a major proportion of CML patients.
K M
KM
Abdulkadyrov
O A
OA
Rukavitsyn
S S
SS
Bessmel'tsev
V Iu
VIu
Udal'eva
I S
IS
Martynkevich
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001854:Bone Marrow Cells / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013997:Time Factors
D000970:Antineoplastic Agents; D016898:Interferon-alpha
Effektivnost' lecheniia nativnym limfoblastoidnym alfa-interferonom (vellferonom) bol'nykh khronicheskim mieloleĭkozom.